Promoting research partnerships 

to improve veterans’ health

DoD Funding Opportunities for Kidney Cancer Research

24 Jun 2019 10:22 AM | Hawk Tran (Administrator)

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

https://cdmrp.army.mil/funding/kcrp

Academy of Kidney Cancer Investigators - Dean Award – Letter of Intent due September 17, 2019

Dean must be an established kidney cancer researcher.

·      Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.

·      Academy Dean will oversee an interactive virtual academy of Early-Career Investigators and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the Early-Career Investigators.

·     Maximum funding of $625,000 for direct costs (plus indirect costs).

·      Maximum period of performance 5 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Academy of Kidney Cancer Investigators - Early Career Investigator Award – Letter of Intent due September 17, 2019

Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of full application submission deadline.

Letter attesting to eligibility required.

·      Supports addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.

·      Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

·      A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.

·      The Designated Mentor not required to be at the same institution as the Early-Career Investigator.

·      Preliminary data required.

·      Clinical trials are not allowed.

·     Maximum funding of $725,000 for direct costs (plus indirect costs).

·      Maximum period of performance 4 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Consortia Award – Letter of Intent due September 17, 2019

Independent Investigators at or above the level of Assistant Professor (or equivalent)

·      Supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.

·      Funds may not be used for research or development of clinical protocols.

·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.

·      One Coordinating Center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.

·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

·      Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.

·      The consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

Coordinating Center:

·      Maximum funding of $3M for direct costs (plus indirect costs).

·     Maximum period of performance is 3 years.

·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Trial Sites:

·     Maximum funding of $600,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software